Bereich
Infektiologie | Infektionsprävention | Reisemedizin
INFEKT · Dept. I
Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study
Bürgisser P, Vernazza P, Flepp M, Böni J, Tomasik Z, Hummel U, Pantaleo G, Schüpbach J. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 2000; 23:138-44.
01.02.2000Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study
01.02.2000Journal of acquired immune deficiency syndromes (1999) 2000; 23:138-44
Bürgisser P, Vernazza Pietro, Flepp M, Böni J, Tomasik Z, Hummel U, Pantaleo G, Schüpbach J
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study
Vernazza P, Fiscus S, Cohen M, Boggian K, Roth F, Schock J, Cone R, Flepp M, Troiani L, Eron J. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (London, England) 2000; 14:117-21.
28.01.2000Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study
28.01.2000AIDS (London, England) 2000; 14:117-21
Vernazza Pietro, Fiscus S A, Cohen M S, Boggian K, Roth F, Schock J, Cone R W, Flepp M J, Troiani L, Eron J J
Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study
Opravil M, Lüthy R, Roos M, Knuchel M, Huber W, Ott P, Bisset L, Lorenzi P, Bassetti S, Vernazza P, Fischer M, Cone R, Weber R. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 2000; 23:17-25.
01.01.2000Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study
01.01.2000Journal of acquired immune deficiency syndromes (1999) 2000; 23:17-25
Opravil M, Lüthy R, Roos M, Knuchel M C, Huber W, Ott P, Bisset L R, Lorenzi P, Bassetti S, Vernazza Pietro, Fischer M, Cone R W, Weber R
Prevalence of hepatitis C infection in Malawi and lack of association with sexually transmitted diseases
Maida M, Daly C, Hoffman I, Cohen M, Kumwenda M, Vernazza P. Prevalence of hepatitis C infection in Malawi and lack of association with sexually transmitted diseases. European journal of epidemiology 2000; 16:1183-4.
01.01.2000Prevalence of hepatitis C infection in Malawi and lack of association with sexually transmitted diseases
01.01.2000European journal of epidemiology 2000; 16:1183-4
Maida M J, Daly C C, Hoffman I, Cohen M S, Kumwenda M, Vernazza Pietro
[HIV 1999: suppression at what price?]
Vernazza P. [HIV 1999: suppression at what price?]. Schweizerische medizinische Wochenschrift 1999; 129:2010-3.
28.12.1999[HIV 1999: suppression at what price?]
28.12.1999Schweizerische medizinische Wochenschrift 1999; 129:2010-3
Vernazza Pietro
Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study
Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS (London, England) 1999; 13:2547-54.
24.12.1999Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study
24.12.1999AIDS (London, England) 1999; 13:2547-54
Junghans C, Low N, Chan P, Witschi A, Vernazza Pietro, Egger M
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA : the journal of the American Medical Association 1999; 282:2220-6.
15.12.1999AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
15.12.1999JAMA : the journal of the American Medical Association 1999; 282:2220-6
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza Pietro, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A
HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
Wendland T, Furrer H, Vernazza P, Frutig K, Christen A, Matter L, Malinverni R, Pichler W. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS (London, England) 1999; 13:1857-62.
01.10.1999HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
01.10.1999AIDS (London, England) 1999; 13:1857-62
Wendland T, Furrer H, Vernazza Pietro, Frutig K, Christen A, Matter L, Malinverni R, Pichler W J
Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
Zinkernagel C, Ledergerber B, Battegay M, Cone R, Vernazza P, Hirschel B, Opravil M. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study. AIDS (London, England) 1999; 13:1587-9.
20.08.1999Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
20.08.1999AIDS (London, England) 1999; 13:1587-9
Zinkernagel C, Ledergerber B, Battegay M, Cone R W, Vernazza Pietro, Hirschel B, Opravil M
Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study
Schlegel M, Osterwalder J, Galeazzi R, Vernazza P. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ (Clinical research ed.) 1999; 319:352.
07.08.1999Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study
07.08.1999BMJ (Clinical research ed.) 1999; 319:352
Schlegel Matthias, Osterwalder Joseph, Galeazzi R L, Vernazza Pietro
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
Bassetti S, Bernasconi E, Vernazza P, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9.
01.06.1999Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
01.06.1999Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9
Bassetti S, Bernasconi E, Vernazza Pietro, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
Furrer H, Flepp M, Rickenbach M, Vernazza P, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. The New England journal of medicine 1999; 340:1301-6.
29.04.1999Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
29.04.1999The New England journal of medicine 1999; 340:1301-6
Furrer H, Flepp M, Rickenbach M, Vernazza Pietro, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza P, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
13.03.1999Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
13.03.1999Lancet 1999; 353:863-8
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza Pietro, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R
Sexual transmission of HIV: infectiousness and prevention
Vernazza P, Eron J, Fiscus S, Cohen M. Sexual transmission of HIV: infectiousness and prevention. AIDS (London, England) 1999; 13:155-66.
04.02.1999Sexual transmission of HIV: infectiousness and prevention
04.02.1999AIDS (London, England) 1999; 13:155-66
Vernazza Pietro, Eron J J, Fiscus S A, Cohen M S
[HIV 1998: eradication dreams?]
Vernazza P. [HIV 1998: eradication dreams?]. Schweizerische medizinische Wochenschrift 1998; 128:2019-22.
26.12.1998[HIV 1998: eradication dreams?]
26.12.1998Schweizerische medizinische Wochenschrift 1998; 128:2019-22
Vernazza Pietro
Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
Bisset L, Cone R, Huber W, Battegay M, Vernazza P, Weber R, Grob P, Opravil M. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:2115-23.
12.11.1998Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
12.11.1998AIDS (London, England) 1998; 12:2115-23
Bisset L R, Cone R W, Huber W, Battegay M, Vernazza Pietro, Weber R, Grob P J, Opravil M
Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission
Eron J, Vernazza P, Johnston D, Seillier-Moiseiwitsch F, Alcorn T, Fiscus S, Cohen M. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS (London, England) 1998; 12:F181-9.
22.10.1998Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission
22.10.1998AIDS (London, England) 1998; 12:F181-9
Eron J J, Vernazza Pietro, Johnston D M, Seillier-Moiseiwitsch F, Alcorn T M, Fiscus S A, Cohen M S
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
Rutschmann O, Perrin L, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:F71-7.
28.05.1998A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
28.05.1998AIDS (London, England) 1998; 12:F71-7
Rutschmann O T, Perrin L H, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H C, Vernazza Pietro, Malinverni R, Iten A, Opravil M, Hirschel B
[Sexual transmission of HIV: effect of potent antiretroviral therapy]
Vernazza P. [Sexual transmission of HIV: effect of potent antiretroviral therapy]. Therapeutische Umschau. Revue thérapeutique 1998; 55:285-8.
01.05.1998[Sexual transmission of HIV: effect of potent antiretroviral therapy]
01.05.1998Therapeutische Umschau. Revue thérapeutique 1998; 55:285-8
Vernazza Pietro
The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages
Borg-von Zepelin M, Beggah S, Boggian K, Sanglard D, Monod M. The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 1998; 28:543-54.
01.05.1998The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages
01.05.1998Mol Microbiol 1998; 28:543-54
Borg-von Zepelin M, Beggah S, Boggian Katia, Sanglard D, Monod M